Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$93.05 USD

93.05
613,136

+1.21 (1.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $93.08 +0.03 (0.03%) 5:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why Investors Should Invest in Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on strong growth in the Diagnostics business and upbeat guidance.

Zacks Equity Research

QIAGEN (QGEN) Extends QIAwave Product Line With New Kit

by Zacks Equity Research

QIAGEN's (QGEN) new QIAwave kits broaden its selection of environmentally friendly products and reaffirm its commitment to helping researchers advance science.

Zacks Equity Research

Reasons to Retain Patterson Companies (PDCO) in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Zacks Equity Research

HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024

by Zacks Equity Research

HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.

Zacks Equity Research

3 Reasons to Hold HealthEquity (HQY) Stock in Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Zacks Equity Research

Abbott (ABT) Closes Acquisition Deal of Bigfoot Biomedical

by Zacks Equity Research

Abbott's (ABT) footprint in the diabetes care market is increased by the Bigfoot Biomedical acquisition.

Zacks Equity Research

Hologic (HOLX) to Boost Breast Imaging Modality With New Pact

by Zacks Equity Research

Hologic's (HOLX) collaboration with Bayer will enable physicians everywhere to include CEM in their breast cancer diagnosis workflows.

Zacks Equity Research

3 Reasons to Hold Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?

by Zacks Equity Research

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.

Zacks Equity Research

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MF

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MF.

Zacks Equity Research

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Zacks Equity Research

Walgreens (WBA) New Study Shows Medical Adherence Importance

by Zacks Equity Research

Walgreens' (WBA) latest research findings highlight the importance of patients adhering to their therapy.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.

Zacks Equity Research

3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Zacks Equity Research

Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities

by Zacks Equity Research

Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.

Zacks Equity Research

Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.

Zacks Equity Research

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Zacks Equity Research

Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio

by Zacks Equity Research

Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.

Zacks Equity Research

Here's Why HealthEquity (HQY) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Zacks Equity Research

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Zacks Equity Research

DexCom (DXCM) Launches Latest CGM Sensor ONE in France

by Zacks Equity Research

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

Zacks Equity Research

Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes

by Zacks Equity Research

Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain Fresenius Medical (FMS) for Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.